Global Achalasia Treatment Market Study Reveals Growth Factors and Competitive Outlook for Future With Competition Tracking- Allergan, Ipsen Biopharmaceuticals, Nestlé Skin Health (Galderma S.A.), Merz Pharma, Aesculap and Silex Medical

Increasing number of patients in medical centers demanding for safe non-surgical treatments is expected to drive the demand for pneumatic dilation achalasia treatment. In addition, growing demand for fastest and simplest technique is likely to further drive the demand for pneumatic dilation achalasia treatment. Low-risk and cost-effectiveness associated with pneumatic dilation is likely to offer growth opportunities for achalasia treatment market. Single session of the pneumatic dilation achalasia treatment is expected to provide relief for nearly seven years and follow up can be done as and when necessary. Women and older patients are witnessed as being majorly benefitted with pneumatic dilation achalasia treatment across the globe.

Claim Sample Report For FREE- https://www.factmr.com/connectus/sample?flag=S&rep_id=992

Demand for POEM (Peroral Endoscopic Myotomy) to Take an Upsurge

The major factor driving the demand for POEM achalasia treatment is minimal patient discomfort and quicker recovery. In addition, POEM achalasia treatment helps in eliminating scars visibility, improves quality of life and moreover, eliminates the concern regarding hernias, which is likely to form at the laparoscopic incision sites.

Specialty clinics are likely to contribute on a major basis towards revenue growth of achalasia treatment market with increasing number of cases amongst children. Key players and manufacturers in achalasia treatment market are focusing on developing unmatched diagnostic tests with innovative treatments.

Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the oesophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing. The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia and postprandial aspiration, among others. Dysphagia is the most common symptom in patients suffering from achalasia. The causes of achalasia are still unknown. Achalasia is associated with abnormalities of oesophageal peristalsis. Achalasia treatment involves the removal of obstructions caused because the lower oesophageal sphincter muscle fails to relax. Drugs such as isosorbide or nifedipine can provide some relief to patients suffering from achalasia. It is estimated that approximately 70% of achalasia cases are more effectively treated by the enlargement of the lower oesophageal sphincter muscle through a procedure known as pneumatic balloon dilation. Achalasia generally affects adults aged between 25 and 60 years. However, it is likely to occur at any age, including childhood. The symptoms of achalasia appear gradually. People suffering from achalasia are expected to be at the risk of developing oesophageal cancer.

Achalasia Treatment Market: Drivers and Restraints

Increasing research grants and R&D expenditure form governments is driving the growth of the global achalasia treatment market. Rising government support is encouraging the development of treatment options for achalasia and are expected to change the landscape of achalasia treatment over the forecast period (2018-2028). Furthermore, the presence of a small number of affected people is likely to put a severe strain on the healthcare system. Rare disorders are supported by well-organized patient advocacy organizations such as National Organization for Rare Disorders (NORD). However, inadequate treatment information about achalasia among healthcare providers is expected to restrain the global achalasia treatment market. In addition, awareness and understanding of rare disorders such as achalasia are often low and several patients are struggling to find adequate information about it. These factors are also expected to hamper the growth of the global achalasia treatment market.

Get Full Report With table of Content- https://www.factmr.com/report/992/achalasia-treatment-market

Achalasia Treatment Market: Segmentation

The global achalasia treatment market has been segmented on the basis of treatment, end user and geography.

Based on treatment, the global achalasia treatment market is segmented as:

Non-Surgical Treatment
Botulinum toxin type A
Pneumatic dilation
Others
Surgical Treatment
Peroral Endoscopic Myotomy (POEM)
Heller Myotomy
Others
Based on End User, the global achalasia treatment market is segmented as:

Hospitals
Specialty Clinics
Research Institutes
Achalasia Treatment Market: Overview

Over the forecast period, achalasia treatment market is expected to witness moderate growth. Approximately 85-90% of achalasia cases can be treated with surgical procedures. During surgical procedures, the muscle fibres in the lower oesophageal sphincter are cut. Among surgical treatment types, the Heller Myotomy segment is expected to lead in the global achalasia treatment market over the forecast period. The hospitals end-user segment is expected to contribute to the maximum market share in the global achalasia treatment market. Achalasia treatment for patients majorly focuses on the improvement of symptoms.

Achalasia Treatment Market: Regional Outlook

Geographically, the global achalasia treatment market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to continue to dominate the global achalasia treatment market owing to the presence of prominent key players and favourable reimbursement scenario in the region. The Asia Pacific achalasia treatment market is expected to grow at a maximum CAGR over the forecast period due to the entry of new players in the region and increasing awareness about achalasia treatment. The Middle East & Africa and Latin America regions are expected to hold a minimum market share in the global achalasia treatment market owing to lack of strategies for access to treatments for achalasia.

Achalasia Treatment Market: Key Players

Some of the key players operating in the global achalasia treatment market are Allergan plc; Ipsen Biopharmaceuticals, Inc.; Nestlé Skin Health (Galderma S.A.); Merz Pharma; Aesculap, Inc. and Silex Medical, LLC.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask Industry Expert about this Report- https://www.factmr.com/connectus/sample?flag=AE&rep_id=992

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at- https://www.industrynewsanalysis.com/

This release was published on openPR.